Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation.
about
Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disordersAblation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.Neuroprotective activities of CEP-1347 in models of neuroAIDS.Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production.Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.HIV-1-Tat excites cardiac parasympathetic neurons of nucleus ambiguus and triggers prolonged bradycardia in conscious rats.Mixed Lineage Kinase 3 deficiency delays viral clearance in the lung and is associated with diminished influenza-induced cytopathic effect in infected cellsAdjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disordersHuman immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders.Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders.Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disordersNovel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis.Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic DamageMixed lineage kinases (MLKs): a role in dendritic cells, inflammation and immunity?Tat engagement of p38 MAP kinase and IRF7 pathways leads to activation of interferon-stimulated genes in antigen-presenting cells.Mitogen-activated protein kinase p38 in HIV infection and associated brain injury.Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction.Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND.Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinaseNeuropharmacologic Approaches to Restore the Brain's Microenvironment.MLK3 promotes melanoma proliferation and invasion and is a target of microRNA-125b.LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein.Ankyrin-rich membrane spanning protein plays a critical role in nuclear factor-kappa B signaling.HIV Tat excites D1 receptor-like expressing neurons from rat nucleus accumbens.Neuronal apoptosis by HIV-1 Vpr: contribution of proinflammatory molecular networks from infected target cells.Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson's disease, as an anti-cancer stem cell drug.Activation of CD40 by soluble recombinant human CD40 ligand inhibits human glioma cells proliferation via nuclear factor-κB signaling pathway.
P2860
Q28082139-1CB9BE14-1E79-497B-98F0-B3CFE952AF27Q30472512-C9ECFCA9-DF89-405C-9D89-C17657DFA988Q33587971-F0AB96A3-9E63-4A8F-9EA9-99396E681642Q33649838-898A6864-9F96-4654-9310-B3752EAEF5B7Q33654498-A71EBA72-F2E1-4311-AA5B-E44EFC707147Q33701989-1B7D7F94-156A-4476-AF1B-E00EF8BABF7FQ33749295-23A6BB83-BEC1-4EB5-9CC5-D3AADAD4F37DQ34507098-5D5216E1-7E64-4194-BDBA-065A8F6DC7A2Q34664366-C91824F3-C3A7-4F83-A7AC-477C236172ECQ34769218-46638574-A3A4-4A19-B584-0ABCEE083078Q35022812-373F0073-C5AF-4E3B-890A-F0CBF5F8E566Q35236882-2F10412C-B543-49C3-B3A4-BBFCEA203642Q36043123-80A77676-AA94-44AD-A0E1-B137AE18B79FQ36439056-23D1E4E5-266A-4F9F-AF66-9A6F2F11BD60Q36780182-1E67FD82-D8BB-4344-8315-A849B51E6DB4Q36850837-B048ECDF-32C8-4E38-88EF-F41364E0B59BQ36950000-BC1FDD72-2B5D-4932-90BE-0452092461C0Q37140177-CFC3F1FC-0E27-4B7A-B361-B2CE380D704CQ37354387-A8285CA8-C2F0-4BA1-A5A6-B09C5ED1574EQ37721505-DADE3DD7-10DA-4076-86E9-DA0CBE8FDBFEQ37794385-B99A6097-AECD-48EC-9032-BC3AD4674390Q38879533-0A6C08E2-4F99-4A70-97F9-0F0C893654BFQ39014798-45CB79B2-C142-4D8A-8468-1C40D9759340Q39236534-2012BF63-A3F5-4F88-A70D-6BCE0C103FF9Q39978945-DA53B3B4-EBA7-4AD4-A5CD-74DDFE063CB7Q40168892-5D63C614-EF27-4B7D-8B2E-4F16A9CF41A4Q41817482-17E8660F-8339-4CBE-8109-DEE96EC2861FQ47136172-1E149685-4CE2-426B-BD24-CE63F700F2DAQ55461922-DBABC3C7-ED0B-47B3-B4E3-0AF1ACDE9634
P2860
Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Inhibition of mixed lineage ki ...... icity and monocyte activation.
@en
Inhibition of mixed lineage ki ...... icity and monocyte activation.
@nl
type
label
Inhibition of mixed lineage ki ...... icity and monocyte activation.
@en
Inhibition of mixed lineage ki ...... icity and monocyte activation.
@nl
prefLabel
Inhibition of mixed lineage ki ...... icity and monocyte activation.
@en
Inhibition of mixed lineage ki ...... icity and monocyte activation.
@nl
P2093
P1476
Inhibition of mixed lineage ki ...... xicity and monocyte activation
@en
P2093
Angela Litzburg
Elizabeth Reisinger
Giovanni Schifitto
Lynn Sniderhan
Sanjay B Maggirwar
Shongshan Fan
P304
P356
10.4049/JIMMUNOL.177.1.702
P407
P577
2006-07-01T00:00:00Z